Our study revealed a positive correlation between SIRPα expression at the tumor site and PD-L1 in colorectal cancer patients (Fig. 1C), suggesting the rationale for simultaneously targeting SIRPα and PD-L1 in colorectal cancer treatment. This evidence concerns the gene CD274 and neoplasm.